Tariro D Chawana1, Monica Gandhi, Kusum Nathoo, Bernard Ngara, Alexander Louie, Howard Horng, David Katzenstein, John Metcalfe, Charles F B Nhachi. 1. *Department of Clinical Pharmacology, University of Zimbabwe, Harare, Zimbabwe; †Division of HIV, Infectious Diseases, and Global Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA; ‡Department of Paediatrics, University of Zimbabwe, Harare, Zimbabwe; §Department of Community Medicine, University of Zimbabwe, Harare, Zimbabwe; ‖Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, CA; and ¶Division of Pulmonary and Critical Care, Department of Medicine, University of California San Francisco, San Francisco, CA.
Abstract
BACKGROUND: Adequate antiretroviral exposure is crucial to virological suppression. We assessed the relationship between atazanavir hair levels with self-reported adherence, virological outcomes, and the effect of a home-based adherence intervention in HIV-infected adolescents failing second-line antiretroviral treatment in Zimbabwe. METHODS:HIV-infected adolescents onatazanavir/ritonavir-based second-line treatment for ≥6 months with viral load (VL) >1000 copies/mL were randomized to either standard care (control) or standard care plus modified directly administered antiretroviral therapy (intervention). Questionnaires were administered; VL and hair samples were collected at baseline and after 90 days in each group. Viral suppression was defined as <1000 copies/mL after follow-up. RESULTS:Fifty adolescents (10-18 years) were enrolled; 23 (46%) were randomized to intervention and 27 (54%) to control. Atazanavir hair concentration <2.35 ng/mg (lower interquartile range for those with virological suppression) defined a cutoff below which most participants experienced virological failure. Male sex (P = 0.03), virological suppression at follow-up (P = 0.013), greater reduction in VL (P = 0.006), and change in average self-reported adherence over the previous month (P = 0.031) were associated with adequate (>2.35 ng/mg) hair concentrations. Participants with virological failure were more likely to have suboptimal atazanavir hair concentrations (RR = 7.2, 95% CI: 1 to 51, P = 0.049). There were no differences in atazanavir hair concentration between the arms after follow-up. CONCLUSIONS: A threshold of atazanavir concentrations in hair (2.35 ng/mg), above which virological suppression was likely, was defined for adolescents failing second-line atazanavir/ritonavir-based ART in Zimbabwe. Male sex and better self-reported adherence were associated with adequate atazanavir hair concentrations. Antiretroviral hair concentrations may serve as a useful clinical tool among adolescents.
RCT Entities:
BACKGROUND: Adequate antiretroviral exposure is crucial to virological suppression. We assessed the relationship between atazanavir hair levels with self-reported adherence, virological outcomes, and the effect of a home-based adherence intervention in HIV-infected adolescents failing second-line antiretroviral treatment in Zimbabwe. METHODS:HIV-infected adolescents on atazanavir/ritonavir-based second-line treatment for ≥6 months with viral load (VL) >1000 copies/mL were randomized to either standard care (control) or standard care plus modified directly administered antiretroviral therapy (intervention). Questionnaires were administered; VL and hair samples were collected at baseline and after 90 days in each group. Viral suppression was defined as <1000 copies/mL after follow-up. RESULTS: Fifty adolescents (10-18 years) were enrolled; 23 (46%) were randomized to intervention and 27 (54%) to control. Atazanavir hair concentration <2.35 ng/mg (lower interquartile range for those with virological suppression) defined a cutoff below which most participants experienced virological failure. Male sex (P = 0.03), virological suppression at follow-up (P = 0.013), greater reduction in VL (P = 0.006), and change in average self-reported adherence over the previous month (P = 0.031) were associated with adequate (>2.35 ng/mg) hair concentrations. Participants with virological failure were more likely to have suboptimal atazanavir hair concentrations (RR = 7.2, 95% CI: 1 to 51, P = 0.049). There were no differences in atazanavir hair concentration between the arms after follow-up. CONCLUSIONS: A threshold of atazanavir concentrations in hair (2.35 ng/mg), above which virological suppression was likely, was defined for adolescents failing second-line atazanavir/ritonavir-based ART in Zimbabwe. Male sex and better self-reported adherence were associated with adequate atazanavir hair concentrations. Antiretroviral hair concentrations may serve as a useful clinical tool among adolescents.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Gert Uves van Zyl; Thijs E van Mens; Helen McIlleron; Michele Zeier; Jean B Nachega; Eric Decloedt; Carolina Malavazzi; Peter Smith; Yong Huang; Lize van der Merwe; Monica Gandhi; Gary Maartens Journal: J Acquir Immune Defic Syndr Date: 2011-04 Impact factor: 3.731
Authors: Monica Gandhi; Niloufar Ameli; Peter Bacchetti; Kathryn Anastos; Stephen J Gange; Howard Minkoff; Mary Young; Joel Milam; Mardge H Cohen; Gerald B Sharp; Yong Huang; Ruth M Greenblatt Journal: Clin Infect Dis Date: 2011-05 Impact factor: 9.079
Authors: Constance A Nyamukapa; Simon Gregson; Ben Lopman; Suzue Saito; Helen J Watts; Roeland Monasch; Matthew C H Jukes Journal: Am J Public Health Date: 2007-11-29 Impact factor: 9.308
Authors: Celestin Bakanda; Josephine Birungi; Robert Mwesigwa; Jean B Nachega; Keith Chan; Alexis Palmer; Nathan Ford; Edward J Mills Journal: PLoS One Date: 2011-04-29 Impact factor: 3.240
Authors: Nhi Phung; Karen Kuncze; Hideaki Okochi; Alexander Louie; Leslie Z Benet; Igho Ofokotun; David W Haas; Judith S Currier; Tariro D Chawana; Anandi N Sheth; Peter Bacchetti; Monica Gandhi; Howard Horng Journal: Rapid Commun Mass Spectrom Date: 2018-03-15 Impact factor: 2.419
Authors: Matthew A Spinelli; Jessica E Haberer; Peter R Chai; Jose Castillo-Mancilla; Peter L Anderson; Monica Gandhi Journal: Curr HIV/AIDS Rep Date: 2020-08 Impact factor: 5.071
Authors: Pamela M Murnane; Peter Bacchetti; Judith S Currier; Sean Brummel; Hideaki Okochi; Nhi Phung; Alexander Louie; Karen Kuncze; Risa M Hoffman; Teacler Nematadzira; Dean K Soko; Maxensia Owor; Friday Saidi; Patricia M Flynn; Mary G Fowler; Monica Gandhi Journal: AIDS Date: 2019-08-01 Impact factor: 4.177
Authors: Zachary J Tabb; Blandina T Mmbaga; Monica Gandhi; Alexander Louie; Karen Kuncze; Hideaki Okochi; Aisa M Shayo; Elizabeth L Turner; Coleen K Cunningham; Dorothy E Dow Journal: AIDS Date: 2018-06-01 Impact factor: 4.177
Authors: Hideaki Okochi; Alexander Louie; Nhi Phung; Kevin Zhang; Regina M Tallerico; Karen Kuncze; Matthew A Spinelli; Catherine A Koss; Leslie Z Benet; Monica Gandhi Journal: Drug Test Anal Date: 2021-04-13 Impact factor: 3.234